The role of proteasome in malignant diseases
- PMID: 17935285
The role of proteasome in malignant diseases
Abstract
Proteasomal degradation is the main mechanism accounting for intracellular protein degradation. Not only is the proteasome involved in physiological protein turnover, it is also called into play by processes such as signal transduction, cell cycle, and apoptosis. Despite the ubiquitous distribution of the proteasome and its putative essential function, proteasome inhibitors have been developed that can be safely administered with acceptable side effects. Importantly, these compounds have been found to possess antitumor activity and are presently incorporated into the treatment of multiple myeloma and mantle cell lymphoma. In 2003, bortezomib (velcade) was the first compound in this category to have received FDA approval. The mechanisms for the antitumor activity of bortezomib and related drugs remain elusive. NF- kappaB inhibition by proteasome inhibitors may play a role in some instances. Recently, terminally differentiated plasma cells have been shown to downregulate proteasome expression and overall proteasome activity, which may account for the exquisite susceptibility of multiple myeloma cells to proteasome inhibition. New proteasome inhibitors with improved pharmacological properties are being developed and will soon enter clinical experimentation. Finally, studies addressing the usefulness of these compounds in other types of malignancies are ongoing and may soon expand the number of applications of these new therapeutic agents.
Similar articles
-
Proteasome inhibition: a new approach for the treatment of malignancies.Bull Cancer. 2005 Nov;92(11):E61-6, 945-52. Bull Cancer. 2005. PMID: 16316823 Review. English, French.
-
Bortezomib: a novel therapy approved for multiple myeloma.Clin Adv Hematol Oncol. 2003 Oct;1(10):596-600. Clin Adv Hematol Oncol. 2003. PMID: 16258456 Review.
-
[Proteasome inhibitor bortezomib as an anticancer drug].Tanpakushitsu Kakusan Koso. 2006 Aug;51(10 Suppl):1251-6. Tanpakushitsu Kakusan Koso. 2006. PMID: 16922383 Review. Japanese. No abstract available.
-
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.Cancer. 2005 Nov 1;104(9):1794-807. doi: 10.1002/cncr.21414. Cancer. 2005. PMID: 16178003 Review.
-
Proteasome inhibition as a novel therapeutic target in human cancer.J Clin Oncol. 2005 Jan 20;23(3):630-9. doi: 10.1200/JCO.2005.11.030. J Clin Oncol. 2005. PMID: 15659509 Review.
Cited by
-
Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.Am J Transl Res. 2009;1(1):1-15. Epub 2009 Jan 1. Am J Transl Res. 2009. PMID: 19966933 Free PMC article.
-
Safranal induces DNA double-strand breakage and ER-stress-mediated cell death in hepatocellular carcinoma cells.Sci Rep. 2018 Nov 16;8(1):16951. doi: 10.1038/s41598-018-34855-0. Sci Rep. 2018. PMID: 30446676 Free PMC article.